The World Health Organization (WHO) predicts cerebrovascular diseases and neurological disorders account for about 7.1% of the global disease burden. Consequently, businesses are conducting research and preclinical studies examining stem cells' ability to regenerate in treating neurological diseases. Furthermore, the increasing need for potent treatments to decrease disease burden during the forecast period is another factor boosting the market growth.
Access Full Report @ https://www.databridgemarketresearch.com/ar/reports/global-stem-cell-therapy-market
Data Bridge Market Research analyses that the Global Stem Cell Therapy Market, which is USD 257 million in 2023, is expected to reach USD 921.12 million by 2030, at a CAGR of 17.3% during the forecast period 2023 to 2030. The increasing demand for the stem cell therapy will provide potential opportunities for the market growth in the forecast period.
Increasing incidence of chronic disease is anticipated to drive the market's growth rate
Chronic diseases, which include musculoskeletal disorders, cancer, neurology disorders, chronic injuries, and cardiovascular and gastrointestinal can lead to hospitalization, long-term disability, decreased quality of life, and death. The mesenchymal stem cells penetrate and integrate into multiple organs, repair cardiovascular, lung, and spinal cord injuries, and enhance the state of autoimmune diseases, liver, bone, and cartilage diseases. For instance, in 2021, the World Health Organization (WHO) data showed that around 1.7 billion people had musculoskeletal disorders worldwide. Low back pain causes an increasing burden of musculoskeletal conditions.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, Israel, Egypt, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Athersys Inc. (U.S.), Mesoblast Ltd (Australia), Biorestorative Therapies Inc. (U.S.), Pluristem Inc. (Israel), Brainstorm Cell Limited. (U.S.), ViaCyte Inc. (U.S.), Gamida Cell (U.S.), HOPE BIOSCIENCES (U.S.), Cellular Biomedicine Group (U.S.), Smith+Nephew (U.K.), MEDIPOST (South Korea), ANTEROGEN. C.O., LTD. (South Korea), NuVasive Inc. (U.S.), RTI Surgical (U.S.), AlloSource (U.S.), JCR Pharmaceuticals Co. Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand
|
Segment Analysis:
The global stem cell therapy market is categorized into five segments: product type, type application, end user, and distribution channel.
- On the basis of product type, the global stem cell therapy market is segmented into placental/umbilical stem cell, bone marrow derived mesenchymal cells, adipose tissue derived mesenchymal stem cells, and others.
The bone marrow derived mesenchymal stem cells segment of product type segment is anticipated to dominate the stem cell therapy market
The bone marrow derived mesenchymal stem cells segment is expected to dominate the global stem cell therapy market with a share of 44.02% as bone marrow-derived mesenchymal stem cells, are used as a tool to cure degenerative changes in joints and to reconstruct bones and cartilage
- On the basis of type, the global stem cell therapy market is segmented into allogenic stem cell therapy and autologous stem cell therapy.
The allogeneic stem cell therapy segment of type segment is anticipated to dominate the stem cell therapy market
The allogeneic stem cell therapy segment is expected to dominate the global stem cell therapy market with a share of 82.0% since the allogenic stem cell therapy avoids contamination of tumor cells and allogenic stem cell therapy are commonly used for treatment in musculoskeletal disorders.
- On the basis of application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, acute graft-versus-host disease (agvhd), surgeries, gastrointestinal diseases, cardiovascular diseases and other applications. The musculoskeletal disorders segment is expected to dominate the global stem cell therapy market with a share of 25.0% due to increase in technological advancements in biomedical diagnostics.
- On the basis of end user, the global stem cell therapy market is segmented into hospitals and surgical centers, therapeutic companies, services companies, and others. The hospitals and surgical centers, segment is expected to dominate the global stem cell therapy market with a share of 78.8% due to the wide availability of stem cell therapeutics, increased funding and investment by government and private companies and ongoing clinical trials.
- On the basis of distribution channel, the global stem cell therapy market is segmented into direct tenders and third party distributors. The direct tender segment is expected to dominate the global stem cell therapy market with a share of 94.9% due to the increase in demand for stem cell therapy services by the major market players and guaranteed payment.
Major Players
Data Bridge Market Research recognizes the following companies as the major stem cell therapy market players in stem cell therapy market are Athersys Inc. (U.S.), Mesoblast Ltd (Australia), Biorestorative Therapies Inc. (U.S.), Pluristem Inc. (Israel), Brainstorm Cell Limited. (U.S.), ViaCyte Inc. (U.S.), Gamida Cell (U.S.), HOPE BIOSCIENCES (U.S.), Cellular Biomedicine Group (U.S.), Smith+Nephew (U.K.), MEDIPOST (South Korea), ANTEROGEN. C.O., LTD. (South Korea), NuVasive Inc. (U.S.), RTI Surgical (U.S.), AlloSource (U.S.), JCR Pharmaceuticals Co. Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan).
Market Development
- In 2021, Minovia Therapeutics, Ltd. and Astellas Pharma Inc. formed a collaboration and worldwide license agreement to research, develop, and commercialize stem cell therapy programs for diseases caused due to mitochondrial dysfunction. The partnership aims to boost the creation of allogenic mitochondrial cell therapy programs.
- In 2020, Holostem Terapie Avanzate S.r.l. signed an agreement with the Chiesi Group to transfer the business branch of Holoclar. The agreement enabled both market players to focus on their strategic roles to increase the development and production of stem cell therapy procedures.
Regional Analysis
Geographically, the countries covered in the stem cell therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, Israel, Egypt, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in stem cell therapy market during the forecast period 2023 to 2030
North America dominates the stem cell therapy market due to the growing usage of stem cell technology. North America will continue to dominate the stem cell therapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period because of the increasing healthcare expenditure.
Asia-Pacific is estimated to be the fastest-growing region in the stem cell therapy market the forecast period 2023 to 2030
Asia-Pacific is expected to grow from 2023 to 2030 due to the growing number of biotechnology centers and research activities in this region. In addition to this, the increasing presence of major market players and growing disposable income are anticipated to boost the market's growth rate in this region.
For more detailed information about Stem cell therapy market report, click here – https://www.databridgemarketresearch.com/ar/reports/global-stem-cell-therapy-market
